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Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus
8 (HHV-8), is the etiological agent of Kaposi’s sarcoma (KS), and is also associated with
two B cell malignancies, primary effusion lymphoma and multicentric Castleman's disease.
The distribution of KSHV varies globally with high prevalence in some areas of subSaharan Africa (SSA), where seroprevalence can be as high as 80%. It is estimated that
nearly 44,000 new cases of KS emerge annually globally, with the highest incidents
occurring in Africa, where KSHV is endemic. Currently, there is no prophylactic vaccine
against KSHV, and efforts to develop prophylactic vaccines have been limited.
Elicitation of neutralizing antibodies (nAbs) often correlates with protection during
viral infections in humans, but it is not clear whether nAbs against KSHV will also convey
protection against infection. KSHV initiates infection via interaction with various receptors

on the surface of target cells, which is primarily mediated by multiple viral glycoproteins
embedded in the viral envelope. These glycoproteins play important roles in virion
attachment and entry into target cells, therefore they could be potential targets for KSHVspecific nAbs. Characterization of the human neutralizing antibody responses against
KSHV envelope glycoproteins and identifying the targets of these antibodies, are needed
for designing an effective vaccine against KSHV.
KSHV virions incorporate eight glycoproteins into their envelope: ORF8 (gB), ORF28,
ORF68, ORF22 (gH), ORF47 (gL), ORF39 (gM), ORF53 (gN) and gpK8.1. Through
testing the ability of each KSHV glycoprotein in recognizing/adsorbing KSHV-specific
nAbs by this study, it was determined that multiple KSHV glycoproteins were able to bind
to these antibodies in a majority of KSHV infected individuals. In addition, the ability of
each KSHV glycoprotein in depleting the KSHV nAbs from KSHV positive plasma varied
among individuals. Among all the KSHV envelope glycoproteins, gH/gL complex showed
high adsorption/recognition levels of KSHV-specific nAbs in 80% of the participants
analyzed. These findings suggest that nAbs responses are variable in KSHV infected
individuals, and multiple KSHV envelope glycoproteins are the targets of KSHV-specific
nAbs, with gH/gL complex being the most predominant target, which can serve as a
potential target antigen for developing prophylactic vaccines against KSHV.
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Chapter 1
Literature Review
I.

General biology of human herpesviruses

Herpesviruses belong to the herpesviridae family and are divided into three subfamilies
of α herpesviruses, β herpesviruses, and γ herpesviruses based on their biological
properties. Alpha herpesviruses have a broader host range than β herpesviruses, however,
γ herpesviruses have even more restricted hosts than β herpesviruses (Whitley, 1996). The
viral DNA of herpesviridae replicates in the host cell nucleus of a wide range of vertebrates
including, humans, mice, horses, cattle, pigs, fish, and even in some invertebrates such as
oysters (Davison, 2010). Herpesviruses are widespread among humans, and more than 90%
of adults are infected with at least one herpesvirus which then can remain in a latent form
lifelong (Whitley, 1996).
There are more than 130 known herpesviruses, of which 8 can infect humans: herpes
simplex virus types 1 and 2 (HSV-1 and HSV-2, also known as HHV1 and HHV2);
varicella-zoster virus (VZV); Epstein-Barr virus (EBV); human cytomegalovirus (HCMV
or HHV-5); human herpesvirus 6A and 6B (HHV-6A and HHV-6B); human herpesvirus 7
(HHV-7); and Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human
herpesvirus-8 (HHV-8) (Brown and Newcomb, 2011; Whitley, 1996). A similar virion
structure is shared among all herpesviruses, which is comprised of a core containing a
relatively large, linear, double-stranded DNA genome encoding 70 to 200 genes. The viral
genome is encapsidated in an icosahedral nucleocapsid composed of 162 capsomere
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subunits, which itself is surrounded by a protein coat called tegument containing both viral
proteins and viral mRNAs, and a lipid bilayer envelope obtained from the host cell which
harbors a number of viral glycoproteins (Brown and Newcomb, 2011).
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II.

KSHV epidemiology

Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus8 (HHV-8), the most recently identified member of the herpesviridae, is the etiological
agent of all types of Kaposi’s sarcoma (KS) (endemic KS, epidemic KS, Classical KS and
Iatrogenic KS) and also two lymphoproliferative diseases, primary effusion lymphoma
(PEL) and multicentric Castleman's disease (MCD) (Chang et al., 1994; Sousa-Squiavinato
et al., 2015). It is estimated that 44,000 new cases of Kaposi’s sarcomas emerge each year,
with the highest incidents occurring in Africa, where the virus is endemic (Bray et al., 2018;
Torre et al., 2015). The seroprevalence of KSHV differs globally; with high rates in Africa
and South America of between 30 to 80 percent, which is considered to be endemic,
intermediate rates in the Mediterranean regions, 4 to 35 percent, and less than 10 percent
in North America, Western Europe and Asia (Casper, 2011; Dedicoat and Newton, 2003;
Gao et al., 1996; Rohner et al., 2014; Simpson et al., 1996; Whitby et al., 1998).
There are four clinical presentations of KS: Classical KS (CKS), a rare disease found
in elderly men of Mediterranean and Eastern European decent; Endemic KS (EnKS), a
more aggressive form of KS than classical KS found among HIV-1 negative individuals in
Africa; Epidemic KS (EpKS), the most aggressive form of KS which is associated with
HIV-1 co-infection; and Iatrogenic or posttransplant KS (IKS), which is associated with
clinical procedures involving immunosuppressive therapies (Dollard et al., 2005; Moore
and Chang, 1995, 1998). A vaccine for KSHV is not currently available but is needed,
especially with decades of research, optimal treatments for KS remain poorly defined, and
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clinical outcomes are particularly unfavorable in resource-limited settings (Gao et al.,
1996).
KSHV transmission occurs largely via saliva, sexual contact, and in some rare cases
through organ transplantation and blood transfusion (Alexander et al., 1998; Barozzi et al.,
2003; Brayfield et al., 2004; Butler et al., 2011; Johnston et al., 2009; Mbulaiteye et al.,
2004; Pauk et al., 2000). KSHV-associated malignancies are primarily present in people
with acquired immunodeficiency syndrome (AIDS) and induced immunosuppression in
organ transplant recipients (Bouvard et al., 2009; Parkin, 2006). KS is a major cause of
sickness and death in adults in sub-Saharan Africa, where the prevalence of HIV/AIDS is
still high, and a great threat to children as well (Feller et al., 2010; Mbulaiteye et al., 2006;
Wabinga et al., 2000). Some early reports from sub-Saharan Africa revealed that maternal
seropositivity for KSHV is a risk factor for infection among children, indicating a
likelihood of mother to child transmission (Bourboulia et al., 1998). Despite a significant
reduction in the incidence of KS cases since the introduction of antiretroviral therapy
(ART), there are still a considerable number of new cases of KS arising each year
worldwide (Bray et al., 2018; Torre et al., 2015). In addition, only about 50% of patients
can accomplish a complete resolution of KS lesions with ART treatment, all justifying the
need to develop a vaccine to project against KSHV infection. However, to date, there have
not been significant efforts to develop a prophylactic vaccine against KSHV, with no
reported preclinical or clinical vaccine trial in the last three decades (Nguyen et al., 2008;
Wu et al., 2012).
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III.

KSHV life cycle

KSHV contains a large linear double-stranded DNA genome of approximately 160 Kb
in size and encodes more than 100 open reading frames (ORFs), from which ORFs 4-75
are named by their homology with HSV ORFs (Dourmishev et al., 2003). Like all other
herpesviruses, KSHV displays two distinct phases of life cycle; latent infection and lytic
reactivation, which can be differentiated based on the viral genes that are being expressed,
allowing the virus to transition between silent and active life cycle (Cai et al., 2010; Ye et
al., 2011). During latency, which can persist for life, few viral genes are expressed in the
infected cells. At this stage of infection, the viral genome circularizes in the nucleus and is
maintained as a chromatinized nuclear episome, and no virion production is observed
(Ballestas et al., 1999). Latency can be interrupted, and the virus can switch to lytic life
cycle either spontaneously or via induced reactivation. As reactivation occurs, lytic genes
are expressed and the assembly of new virions begins in the nucleus (Gradoville et al.,
2000).
In KS lesions, only a small number of cells are going through lytic reactivation (i.e.
lytically replicating), and most tumor cells are latently infected with KSHV. As a result,
viral latent infection and latent genes are primarily essential for the development of KSHV
induced malignancies (Giffin and Damania, 2014). The major viral genes expressed during
KSHV latency are ORF71 (v-FLIP), ORF72 (v-Cyclin), ORF73 (latency-associated
nuclear antigen, LANA) and K12/Kaposin (Kaposin A, B and C) (Dittmer et al., 1998;
Kedes et al., 1997; Staskus et al., 1997).
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LANA is expressed predominantly during latency and is the most abundant protein in
latently infected cells. To maintain the viral genome in infected cells, LANA interacts with
the host chromatin proteins to promote binding of the KSHV genome to host genome, thus
avoiding viral genome loss during mitosis (Yan et al., 2019). Another major function of
LANA is its interaction with the p53 protein. The p53 protein, generally referred to as a
tumor suppression protein, is a transcriptional regulator of cell growth. The induction of
p53 commonly leads to either cell cycle arrest or apoptosis. The loss of p53 is believed to
correlate with cellular transformation and tumorigenesis. It has been shown that LANA
interacts with p53 to suppress its transcriptional activity and prevents apoptosis. By
promoting cell survival, LANA contributes directly to viral persistence and oncogenesis in
KS (Friborg et al., 1999). LANA has also been reported to directly bind and inhibit
Replication and Transcription Activator (RTA) promoter activities, therefore suppressing
viral lytic gene expressions (Lan et al., 2004).
The viral cyclin is also expressed predominantly during the latent phase of KSHV viral
cycle, and it is a homolog of cellular cyclin D2 which primarily regulates cell cycle and
cell proliferation. (Jones et al., 2014; Li et al., 1997; Van Dross et al., 2005). The v-cyclin
also phosphorylates the retinoblastoma (Rb) protein. The un-phosphorylated form of Rb
binds to E2F, a transcriptional protein that leads to the transcription and translation of
several S-phase genes to promote cell proliferation by binding to DNA, to prevent E2F
binding to DNA leading to down regulate of S-phase proteins and cell proliferation
(Harbour and Dean, 2000). Phosphorylation of Rb by v-cyclin will prevent Rb from
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binding to E2F to enable it to promote the expression of S-phase genes and consequently
cell proliferation (Harbour and Dean, 2000).
Another viral protein expressed during latent infection is the v-FLIP protein, a homolog
to cellular FLIP. This protein is expressed from one of the three latency associated genes
that are involved in the regulation of proliferation and apoptosis (Dittmer et al., 1998;
Fakhari and Dittmer, 2002; Jenner et al., 2001). It has been suggested that v-FLIP can block
Fas-mediated apoptosis by inhibiting procaspase 8 cleavage (Bertin et al., 1997).
Additionally, v-FLIP inhibits viral reactivation and lytic replication by suppressing AP-1
pathway (Ye et al., 2008).
The latent state of KSHV can be disrupted to enable KSHV to enter a new phase of
replication cycle, lytic reactivation. During lytic reactivation most viral genes are expressed
to replicate the viral DNA using the cellular replication machinery, and new virions are
generated and released from infected cells to spread the infection. The viral ORF50 (RTA)
plays a major role in KSHV lytic reactivation from latency, and a mutant KSHV with RTA
deletion was shown to be incapable of lytic reactivation (Lukac et al., 1999). A number of
studies have demonstrated that RTA can transactivate a series of important viral lytic
genes, including DBP (ORF6), gB (ORF8), DNA polymerase (ORF9), assembly protein
(AP), PAN (non-coding RNA), thymidine kinase (TK ), vIL-6 (K2), ORF37, ORF52,
ORF56, ORF57, ORF59, ORF65, K8, K9 and K1 (Bu et al., 2008; Byun et al., 2002; Chen
et al., 2009). RTA is also capable of auto-activating its own promoter (Deng et al., 2000).
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The K8 encodes the K-bZIP (K8α) protein which belongs to the basic-leucine zipper
(bZIP) family of transcription factors (Tang and Zheng, 2002). Studies have shown two
different functions for this protein; suppressing RTA auto-activation to inhibit lytic gene
expression under certain conditions, and regulating lytic life cycle by promoting viral DNA
replication via interaction with ori-Lyt (Liao et al., 2003; Liu et al., 2018). Upon lytic
reactivation, viral lytic genes encoding different viral structural proteins, including viral
envelope glycoproteins are also being expressed. These proteins are necessary for the
assembly and egress of new infectious virions.
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IV.

KSHV infection and host cell tropism

KSHV has a broad tropism and can infect various cell types including endothelial,
epithelial, B cells, monocytes, macrophages, dendritic, keratinocytes, fibroblasts and
neuronal cells (Chandran, 2010; Chandran and Hutt-Fletcher, 2007; Kikuta et al., 1997;
Pica and Volpi, 2007; Tso et al., 2017). Similar to most DNA viruses, KSHV infects host
cells using the fundamental cellular mechanism of membrane fusion mediated by the
interaction of several viral glycoproteins with target cell receptors (Connolly et al., 2011).
The KSHV infection of target cells is a multistep complex process which involves a
series of interactions between multiple viral envelope glycoproteins with multiple host cell
surface receptors. Different viral glycoproteins and host cell receptors may be involved,
and will vary dependent on the target cells. This process is initiated via host cell receptor
recognition and binding followed by the virus entry into the cytosol. This is acquired either
via direct fusion of the viral envelope with the host cell plasma membrane, or fusion of
viral envelope with the endosomal membranes after the internalization of the virus by
endocytic pathways, including micropinocytosis in some cell types, such as endothelial
HMVEC-d and HUVEC cells. In contrast, clathrin-mediated endocytosis are involved in
other cells types, such as fibroblast HFF cells (Akula et al., 2003; Kerur et al., 2010; Raghu
et al., 2009; Rappocciolo et al., 2008). Then the viral capsid released in the cytoplasm is
transported to the nuclear periphery, where disassembly of the capsid and the release of
viral genome into the nucleus occurs (Chandran, 2010; Connolly et al., 2011).
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V.

KSHV envelope glycoproteins

In addition to encoding envelop glycoproteins gB (ORF8), gH (ORF22), gL (ORF47),
gM (ORF39) and gN (ORF53) which are conserved among herpesviruses, KSHV also
encodes some unique envelope glycoproteins gpK8.1, ORF28 and ORF68 (Neipel et al.,
1997; Russo et al., 1996; Zhu et al., 2005). The KSHV gB is synthesized as a 110-kDa
protein precursor which undergoes further cleavage and processing. The virion envelopeassociated form of gB consists of multimers of the cleaved 75-kDa and 54-kDa
polypeptides that are di-sulfide linked which are associated with high levels of mannose
and complex sugars (Akula et al., 2001a; Baghian et al., 2000; Wang et al., 2003). Similar
to other herpesviruses, KSHV gH, 120-kDa in size, forms a non-covalent complex with
KSHV gL. Studies have shown that gH can be transported to the membrane independently
from gL, however, the interaction with gH is required for efficient transport of gL to the
cell surface (Hahn et al., 2009; Naranatt et al., 2002). KSHV gN is required for functional
processing of gM, and these two glycoproteins form heterodimers (Koyano et al., 2003).
The KSHV gpk8.1 gene codes for two forms of proteins; the 228-amino acid (aa)-long
gpK8.1A and the 167-aa-long gpk8.1B which is processed from gpK8.1A via an in-frame
deletion of 61 amino acids. The gpk8.1A is the predominant component of the KSHV
virion envelope (Raab et al., 1998; Zhu et al., 2005; Zhu et al., 1999). Currently, the roles
played by ORF28 and ORF68 in KSHV infection are still not fully understood.
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VI.

KSHV host cell surface receptors for KSHV

KSHV infection is mediated through virus interaction with host cell receptors. A broad
range of receptors are utilized by KSHV from which the major ones are heparin sulfate
(HS); α3β1, αVβ3 and αVβ5 integrins; DC-SIGN (Dendritic cell specific intracellular
adhesion molecule-3 (ICAM-3) grabbing non-integrin), xCT, CD98, and several members
of Ephrin family receptor tyrosine kinases (Ephs) (Grosskopf et al., 2019; Naranatt et al.,
2002). Treatment of KSHV with soluble HS has been showed to block virus biding to target
cells including, endothelial (HMVEC-d), fibroblast (HFF), B-cell (BJAB), epithelial
(HEK293) and monocyte (THP1) cells (Akula et al., 2001a, 2002; Birkmann et al., 2001;
Hahn et al., 2009; Jarousse et al., 2008; Kabir-Salmani et al., 2008; Kerur et al., 2010;
Naranatt et al., 2002; Veettil et al., 2008; Wang et al., 2003). Studies have suggested that
pre-incubation of virus with soluble α3β1, αVβ3 and αVβ5, and also pre-treatment of cells
with anti- α3β1, αVβ3 and αVβ5 antibodies prevents virus entry but has no effect on virus
binding to HMVEC-d, HFF and THP1 cells (Akula et al., 2002; Garrigues et al., 2008;
Kerur et al., 2010; Veettil et al., 2008). Treatment of cells with mannan (Linear polymer of
mannose, the natural ligand of DC-SIGN) or with anti- DC-SIGN antibodies can inhibit
virus binding and entry into B cells and THP-1 cells (Kerur et al., 2010; Rappocciolo et al.,
2008; Rappocciolo et al., 2006). Pre-treatment of HMVEC-d cells with anti- xCT and
CD98 antibodies have been shown to block virus gene expression, but has no effect on
virus binding and entry (Akula et al., 2002). Treatment of cells with anti- EphA2R
antibodies and incubation of virus with soluble EphA2 blocks virus entry but has no effect
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on virus binding in HMVEC-d and HFF cells (Bhattacharyya et al., 2010; Hahn et al.,
2012).
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VII.

Interaction between viral glycoproteins and host cells surface receptors

KSHV gB is believed to be the major viral envelope glycoprotein involved in the
initiation of virus binding and entry into target cells. KSHV gB mediates virus binding and
entry via its interactions with host cell surface molecules (receptors) heparin sulfate (HS)
and entry receptors α3β1, αVβ3 and αVβ5 integrins in HMVEC-d and HFF cells (Akula et
al., 2001a, 2002; Akula et al., 2001b; Veettil et al., 2008; Wang et al., 2003). KSHV gB
also has the ability to bind to DC-SIGN molecule of B cells due to its high mannose
structure (Hensler et al., 2014). In contrast to other human herpesvirus gB homologs,
KSHV gB is the only glycoprotein that possesses an integrin-binding RGD (Arg-Gly-Asp)
motif; it is located at amino acids 27 to 29 which is thought to be the minimal peptide
region required for interaction with host cell surface integrins. Studies have shown that
α3β1, αVβ3 and αVβ5 integrins play important roles in KSHV infection in HFF, HMVECd, HEK293 and monocytes. A reduction of infection is also observed with RGD peptides
and antibodies against RGD-gB peptide (Akula et al., 2002; Chakraborty et al., 2011;
Garrigues et al., 2008; Kerur et al., 2010; Veettil et al., 2008).
Similar to gB, KSHV gpK8.1 is another envelope glycoprotein that has the ability to
interact and bind to host cell HS molecules (Birkmann et al., 2001; Wang et al., 2001). The
non-covalently linked gH/gL complex has also been shown to interact with HS molecules,
and pre-incubation of virus with anti- gH and gL antibodies can block KSHV entry, but
not KSHV binding in HFF cells (Naranatt et al., 2002). More recent studies have
demonstrated that KSHV gH/gL complex interacts with the KSHV entry receptors EphA2,
EphA4, EphA5 and EphA7 which are important for virus entry and cell-to-cell
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transmission (Grosskopf et al., 2019; Naranatt et al., 2002). The interaction of KSHV
gM/gN heterodimer with host cell receptors is still unknown, however, they are primarily
involved in virus penetration and egress (Koyano et al., 2003).
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VIII. KSHV-specific neutralizing antibodies
Effective prophylactic viral vaccines stimulate an individual’s humoral immune system
to elicit neutralizing antibodies (nAbs) typically against surface glycoprotein(s) that
mediate binding and entry of an infectious agent into the host cells (Nguyen et al., 2008;
Ogembo et al., 2015). These nAbs can recognize, bind and neutralize the biological effects
of the viral antigen. Studies based on influenza have demonstrated that nAbs elicited by
vaccination are capable of preventing viral infection. These nAbs primarily target the viral
membrane surface proteins hemagglutinin (HA) and neuraminidase (NA) (Soema et al.,
2015; van Els et al., 2014). Studies on nAbs from our lab and others have shown that KSHV
infected individuals do not readily develop nAbs in non-KS asymptomatic patients. In
contrast we have found that most KS patients developed nAbs (Kumar et al., 2013). These
findings suggest that KSHV-specific nAbs are incapable of preventing KS, but as in the
case of influenza, they could potentially have the ability to prevent the viral infection by
binding to the viral glycoproteins.
Since KSHV envelope glycoproteins are presented on the viral surface and are critical
for viral entry into permissive cells, they are attractive vaccine antigen candidates for
eliciting nAbs. Over the past few decades, several studies have been conducted to study
the effect of KSHV envelope glycoproteins-specific nAbs on the neutralization of KSHV
infectivity of target cells. One study found that incubation of KSHV with polyclonal rabbit
anti-gB antibodies was able to neutralize the viral infection of HFF cells in a dosedependent manner (50% to 70% inhibition) (Akula et al., 2001a). Other studies have shown
that immunizing mice or rabbits with Newcastle disease virus-like particles (VLP)
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expressing KSHV gpK8.1, gB and gH/gL, either alone or together, can elicit nAb responses
against KSHV (Barasa et al., 2017; Mulama et al., 2019).
A number of studies have also demonstrated that anti- gH, gL, and gpK8.1 antibodies
can neutralize KSHV infection without affecting the virus binding to its target cells
(Naranatt et al., 2002; Wang et al., 2001; Wang et al., 2003). These observations suggest
that these glycoproteins play essential roles in the entry process of the virus. Also, it is
likely that the fusion machinery of KSHV comprises of gB, gH, gL and gpK8.1. Therefore,
these KSHV envelope glycoproteins could potentially be the target(s) of KSHV-specific
nAbs to prevent infection.
Given the critical roles of KSHV glycoproteins in viral entry, we hypothesized that
KSHV glycoproteins play a pivotal role in the elicitation of KSHV-specific nAbs in
infected individuals. To test this hypothesis, we expressed the KSHV glycoproteins in
various expression systems and characterized the nAbs responses in infected individuals.
We further studied the ability of various KSHV glycoproteins in the adsorption/removal of
KSHV-specific nAbs from the plasma of KSHV infected individuals who have high nAbs
titers, to identify the glycoproteins which are most commonly recognized. Our study will
lead to the identification of the viral glycoprotein(s), which could serve as potential vaccine
target(s) to induce a protective nAbs response.
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Chapter 2
KSHV gB can be efficiently expressed in the adenoviral expression and can induce
neutralizing antibodies in mice
Introduction
All herpesviruses initiate infection via binding to various receptors on the surface of
target cells, which is primarily mediated by the viral glycoproteins embedded in the viral
envelope (Subramanian et al., 2008). These glycoproteins play important roles in virus
attachment to target cells, fusion of the viral envelope with either cytoplasmic or
endosomal membranes, and virion morphogenesis and egress (Gao et al., 1996). Kaposi's
sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8),
the most recently identified member of the herpesviridae, is the etiological agent of
Kaposi’s sarcoma (KS) and also two lymphoproliferative diseases, primary effusion
lymphoma (PEL) and multicentric Castleman's disease (MCD) (Chang et al., 1994; SousaSquiavinato et al., 2015). Among all KSHV envelope glycoproteins, glycoprotein B (gB)
is believed to be the essential protein for virus binding and entry into permissive cells,
incorporated into the virion envelope.
KSHV gB initiates virus binding to host cells via its interactions with host cell surface
heparin sulfate (HS), and entry receptors α3β1, αVβ3 and αVβ5 integrins (Akula et al.,
2001a, 2002; Akula et al., 2001b; Veettil et al., 2008; Wang et al., 2003). Additionally,
among all KSHV glycoproteins, only gB possesses the RGD (Arg-Gly-Asp) motif which
is the minimal region of many extracellular matrix (ECM) proteins required for the
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interactions with a subset of host cell surface integrins (Akula et al., 2002; Chakraborty et
al., 2011; Garrigues et al., 2008; Kerur et al., 2010; Veettil et al., 2008). One study found
that incubation of KSHV with polyclonal rabbit anti-gB antibodies was able to neutralize
the viral infection of HFF cells in a dose-dependent manner (50% to 70% inhibition)
(Akula et al., 2001a). Moreover, several studies have shown that mice or rabbits immunized
with Newcastle disease virus-like particles (VLP) expressing gB can elicit nAbs responses
against KSHV (Barasa et al., 2017; Mulama et al., 2019). Collectively, this suggests that
gB plays a major role in KSHV infection of target cells and potentially is the primary target
of KSHV-specific neutralizing antibodies (nAbs), present in the plasma of KSHV infected
individuals.
In this study, we have focused on expressing KSHV gB and characterizing its role in
elicitation of KSHV-specific nAbs. We hypothesized that KSHV envelope glycoprotein
gB is the primary target of the KSHV-specific nAbs, and our immediate approach is to use
a mammalian expression system that would provide us with adequate levels of gB for our
immunization study. To test this hypothesis, we cloned the full length gB gene into a
replication incompetent adenovirus type 5 (Ad5-gB) which has been shown to be a good
delivery and expression system to obtain high expression levels of cloned genes. Next, we
used the expression vector to inoculate mice to elicit antibodies against KSHV gB, and
then tested the ability of these antibodies in neutralizing KSHV.
There are several advantages in using an adenovirus vector compared to other gene
delivery systems. For example, unlike lentivirus, the recombinant adenovirus vector can
avoid activation or inactivation of host genes by remaining epichromosomal. In addition,
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generation of the adenovirus is relatively simple and would yield high virus titers; high
expression levels of the target protein can also be achieved by increasing the multiplicity
of infection (MOI) without significant negative effects on the host cells. Also, adenoviral
vectors have advanced significantly over the years since the first attempts to use them in
gene therapy, and are currently being tested clinically in several gene therapies, anticancer
studies and as vaccine vector (Wold and Toth, 2013).
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Results
Construction of the recombinant Ad-gB and its expression in vitro
The recombinant adenovirus encoding KSHV gB was generated by cloning the full
length gB gene into a replication incompetent adenovirus type 5 vector. To facilitate the
detection of gB, the sequence for the 3xFLAG epitope tag was fused to the carboxylterminus of the glycoprotein. The recombinant adenovirus was then evaluated by
restriction enzyme, and rescued in 293 cells. Next, the expression of gB was assessed in
Vero cells by infection with Ad-gB (Figure 1). At 72 to 120 hours post-infection, intense
brown colored stained cells were demonstrated by immunohistochemical (IHC) staining
using antibody against the 3xFLAG epitope tag, indicating high expression level of KSHV
gB (Figure 2). Non-infected Vero cells served as a negative control and produced no
evident chromagen deposition.

To further confirm gB expression in Vero cells, western blotting was performed on
120-hour Vero infected cells with Ad-gB against 3xFLAG epitope tag to determine the size
of the gB expressed. In parallel Endo H treated lysate was also analyzed to confirm that
the gB expressed is of the expected size of 95 kDa (Figure 3). With total cell lysate without
Endo H treatment, a 140 kDa band was detected for gB which is expected to be larger than
95 kDa because it should be glycosylated. Upon Endo H treated, a 95 kDa band
corresponding to the un-glycosylated gB in the treated lysate was detected, suggesting the
correct size gB was made.
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Examine the ability of Ad-gB to elicit KSHV nAbs in vivo
To evaluate the neutralizing ability of Ad-gB immunized plasma, 4 mice were
inoculated with 10 x 1010 Ad-gB viral particles intramuscularly. Mice were boosted with
10 x 1010 Ad-gB viral particles on day 29 and bled on day 37. Plasma collected at Day 37
were used to conduct KSHV infection neutralization assays. Plasma from mice immunized
with PBS served as the negative control and was used to normalize the percent
neutralization. At 1:18 dilution of plasma a 45-65% neutralization of KSHV infection of
293T cells was observed among the plasma from four mice (Figure 4). This moderate
neutralizing activity of the Ad-gB immunized plasma implicates that there are possibly
other antigenic determinant(s) of KSHV-specific nAbs that needs to be identifies.
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Material and methods

Cell cultures

Human embryonic kidney T (293T), HEK-293, Vero and BC-3 cells were obtained
from ATCC (CRL-3217, CRL-1573, CCL-81and CRL-2277, respectively). HEK-293,
HEK- 293T and Vero cells were maintained in Dulbecco’s modified Eagle medium
(DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S). BC-3
cells were maintained in RPMI with 20% FBS and 1% P/S. Vero.219 cells [a gift from
Jeffrey Vieira (Vieira and O'Hearn, 2004)] stably expressing green fluorescent protein from
the KSHV genome during latency were used to generate recombinant KSHV (rKSHV.219)
and were maintained in DMEM with 10% FBS and 1% P/S and 6 µg/ml of puromycin. All
cell cultures were maintained at 37°C in a 5% CO2 incubator.

Construction of the recombinant Ad-gB

The recombinant adenovirus encoding KSHV gB was generated by cloning PCR
amplified full length sequence (forward [5’-GCTCGGATCCATGACTCCCAGGTCTAGATTGG-3’] and
reverse [5’-GCAGAATTCCTAACTCCCCCGTTTCCGGACTG-3’]) of gB gene from BC-3 genomic

DNA using high fidelity enzyme (Q5 HF DNA polymerase) into a shuttle with 3xFLAG
epitope tag sequence fused to the carboxyl-terminus of the gB genome. Then, the insert
was PCR amplified (forward [5’-AAATGGGCGGTAGGCGTGTAC-3’] and reverse [5’TAGGAAAGGACAGTGGGAGTGGC-3’]) and cloned into a replication incompetent adenovirus

vector type 5. Next, the plasmid was transformed into competent Stellar cells and screened
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by restriction enzyme digestion. The plasmid was then linearized with PacI and transfected
into HEK-293 cells to generate the recombinant adenovirus. Finally, the Ad-gB virus was
purified using cesium chloride (CsCl) density gradient ultra-centrifugation as previously
described (Privatt et al., 2019).

Immunohistochemistry (IHC)
104 cells/chamber of Vero cells were seeded into a 4-chamber slide. At 24-hours post
seeding, the cells were infected with either 500, 1000 or 2000 particles of Ad-gB. IHC was
performed at 3,5 and 7 days post-infection. The slides were washed and fixed in 4%
paraformaldehyde for 30 minutes at room temperature. The fixed slides were then
incubated in 0.3% H2O2 methanol solution for 30 minutes at room temperature, followed
by washes and antigen retrieved in sodium citrate solution for 15 minutes at 98°C. After
cooling to room temperature, the slides were washed and blocked with 10% normal goat
serum for 30 minutes at room temperature and incubated with mouse monoclonal antiFLAG M2 antibody (Sigma-Aldrich) at 1:300 in blocking solution at 4°C overnight. The
next day, the slides were washed and incubated with Dako EnVision+ System-HRP antimouse polymer for 30 minutes at room temperature and color was developed with DAB
solution (Dako). Counterstaining of the nucleus was performed using hematoxylin. The
final stained slides were then air-dried, rinsed twice in xylene solution for 5 minutes each,
and then coverslip was added with Cytoseal 60 (Thermo Scientific). The slides were
examined with a Nikon Eclipse 50i microscope under 20X magnification. Three times 3
fields of pictures (i.e., 9 pictures) were taken at 20X magnification and digitally stitched.
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Immunoblot
106 cells/well of Vero cells were seeded into a 6-well plate. At 24-hours post-seeding,
cells were infected with 1000 viral particles of Ad-gB. After 120 hours, the proteins were
extracted from total cell lysate using RIPA lysis buffer in the presence of protease inhibitor.
Endo H treatment was also performed on extracted proteins according to the
manufacturer’s protocol (New England BioLabs). The extracted protein was then measured
by Pierce BCA protein assay (Thermo Scientific) and equal amounts of protein was loaded
and resolved on a 10% SDS-PAGE. The proteins were then transferred onto a
nitrocellulose membrane. After blocking with 5% skim milk in 1X PBS with 0.5% Tween
20 for 2 hours at room temperature, the membranes were incubated with mouse monoclonal
anti-FLAG M2 antibody (Sigma-Aldrich) at 1:100 or mouse monoclonal anti-GAPDH
(6C5) IgG (Santa Cruz Biotechnology) at 1:2000 as primary antibodies overnight at 4°C.
Next day, after washing, the membranes were incubated with the secondary donkey antimouse 800CW or 680CW antibodies (Li-Cor Biosciences) at 1:10000 for 2 hours at room
temperature, and then washed repeatedly. The membranes were then visualized with
Odyssey infrared imager (Li-Cor Biosciences).
Mice immunization with Ad-gB
Four male CD46 transgenic mice with a C57BL/6 background were immunized with
10 x 1010 Ad-gB viral particles on days 0 and 29 intramuscularly. The mice were bled on
day 37, and then the plasma were tested for neutralizing activity against KSHV.
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Neutralization assay against KSHV
To perform the neutralization assay, the heat inactivated mice plasma (56°C for 1 hour)
were incubated with recombinant KSHV expressing GFP protein (rKSHV.219) at 1:50
dilution at 37°C for 1 hour. HEK-293T cells in 96-well plates (2.5 X 104 cells/well) were
infected with virus-plasma mixture, centrifuged (400g for 20 minutes at room temperature)
and then incubated at 37°C in a 5% CO2 incubator for 72 hours. Neutralization activity of
sera was then analyzed by flow cytometry at 72 hours post-infection as followed:
S
% 𝑛𝑒𝑢𝑡𝑟𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 = 100 − [( ) 𝑋 100]
C
S = % GFP positive cells in wells with Ad-gB immunized mice plasma.
C = % GFP positive cells in wells with PBS immunized mice plasma.
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Discussion
KSHV virions incorporate eight glycoproteins into their envelope, of which
glycoprotein B is believed to be the major protein for attachment and entry into targets
cells due to its interactions with cell surface heparin sulfate molecules and entry via RGD
dependent binding to the integrins. Studies have shown than interruption of gB interactions
with target cell surface molecules would significantly inhibit the infection of target cells
(Akula et al., 2001a). In this study, we attempted to characterize the KSHV nAbs responses
against KSHV gB and to determine if gB is potentially the primary target of KSHV-specific
nAbs.
We showed that infection of Vero cells with Ad-gB resulted in high expression levels
of gB glycoprotein in vitro. Immunization of mice with Ad-gB induced humoral immune
responses, resulting in moderate, about 45-65%, neutralizing activity at 1:18 dilution of
plasma which was not as high as we expected considering the necessity of gB in virus
binding and entry into target cells. However, it was still comparable with a previous study
which showed that immunizing mice with Newcastle disease virus-like particles (VLP)
expressing gB can elicit nAbs responses against KSHV (Barasa et al., 2017). This indicates
that gB can induce KSHV nAbs in immunized animals, and is potentially one of the targets
of the KSHV-specific nAbs. Additionally, because the nAbs responses against gB were
lower than expected, we speculate that other KSHV envelope glycoproteins are necessary
for inducing a stronger neutralizing response against KSHV. To identify all the targets of
the KSHV-specific nAbs, there is a need to characterize the KSHV-specific nAbs responses
in KSHV infected individuals against all the eight KSHV envelope glycoproteins.
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Figure legends
Figure 1. Gel electrophoresis of the digested recombinant adenovirus.
Two bands corresponding to the insert and the empty viral vector at the predicted sizes are
shown. The digestion reaction was done using SwaI enzyme which was previously
introduced into both vector and the insert.
Figure 2. Detection of gB expression via immunohistochemistry (IHC).
Vero cells were infected with Ad-gB, using different amounts of virus input and analyzed
at different time points after infection. IHC was carried out using monoclonal mouse antiFLAG antibody at 1:300 dilution. Brown color stained cells were visualized indicating high
expression level of gB protein.
Figure 3. Detection of gB expression via immunoblot.
Vero cells were infected with Ad-gB, and western blot was performed on RIPA lysed cells,
with or without treatment with Endo H using anti-FLAG antibody at 1:100 dilution. The
gB band was detected by the secondary donkey anti-mouse 800CW antibody via green
color. GAPDH was also investigated using mouse monoclonal anti-GAPDH (6C5) IgG
(Santa Cruz Biotechnology) at 1:2000 as primary antibody and the secondary donkey antimouse 680CW antibody via red color.
Figure 4. Neutralization assay of rKSHV.219 with mice plasma.
Neutralization of rKSHV.219 was carried out using three dilutions (1:9, 1:18 and 1:50) of
heat inactivated plasma from four mice. Plasma from mice immunized with PBS served as
the negative control and was used to normalize the percent neutralization.
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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s
sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in subSahara Africa. The seroprevalence for KSHV is high in the region, and no prophylactic
vaccine against the virus is available. In this study, we characterized the antigenic targets
of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV infected
individuals and KS patients with high nAbs titers. We quantified the extent to which
various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1)
adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our
study revealed that plasma from a majority of KSHV neutralizers recognize multiple viral
glycoproteins. Moreover, the breath of nAbs responses against these viral glycoproteins
varies among endemic KS, epidemic KS and asymptomatic KSHV infected individuals.
Importantly, among the KSHV glycoproteins, the gH/gL complex but neither gH or gL
alone, showed the highest adsorption of KSHV-specific nAbs. This activity was detected
in 80% of the KSHV infected individuals regardless of their KS status. The findings
suggest that the gH/gL complex is the predominant antigenic determinant of KSHVspecific nAbs. Therefore, gH/gL is a potential target for development of KSHV
prophylactic vaccines.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus8 (HHV-8), is the causative agent of all forms of Kaposi sarcoma (KS) and two additional
lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric
Castleman's disease (MCD) (Chang et al., 1994; Sousa-Squiavinato et al., 2015). The
distribution of KSHV varies globally. In some areas such as sub-Saharan Africa (SSA),
KSHV seroprevalence can be as high as 80%; whereas in the US and Europe the prevalence
is 3-20% (Blumenthal et al., 2019; Torre et al., 2015). The prevalence of KS increases
significantly with HIV-1 infection, making it one of the leading cancers among people
living with HIV/AIDS in SSA (Brower, 2011; Mesri et al., 2010). Globally, it is estimated
that nearly 44,000 new cases of KS emerge annually, with the highest incidence occurring
in Africa, where KSHV is endemic (Bray et al., 2018). The two main clinical
manifestations of KS are Endemic KS (EnKS) and Epidemic KS (EpKS). EnKS is found
among HIV-1 negative individuals, whereas EpKS is associated with HIV-1 co-infection
(Moore and Chang, 1995, 1998). Additionally, in specific ethnic groups of elderly men of
Mediterranean or Eastern European descents there exists Classical KS (CKS), and
Iatrogenic KS (IKS) is associated with drug-induced immune suppression (Dollard et al.,
2005). The recurrent rate for KS is high even with chemo or radiotherapy (Krown, 2011).
Therefore, the most cost-effective strategy to reduce KS incidence is to prevent KSHV
infection through vaccination, and understanding the antigenic determinant of KSHVspecific nAbs will contribute to informative vaccine research for KSHV.
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Although KSHV-specific nAbs have been reported in KS patients and KSHV-infected
individuals, their role in KSHV pathogenesis is not known (Kumar et al., 2013; Wakeham
et al., 2015). More importantly, it is unclear whether having KSHV-specific nAbs prior to
exposure to KSHV could be beneficial in preventing its infection and, therefore could serve
as an adaptive correlate of protection against KS development. Based on lessons learned
from vaccination against other viruses, such as influenza, nAbs elicited through vaccination
primarily target viral membrane surface proteins (Soema et al., 2015; van Els et al., 2014).
It has also been shown that immunization with KSHV envelope glycoproteins gB, gpK8.1
and gH/gL can elicit nAbs responses in animal models (Barasa et al., 2017; Mulama et al.,
2019). However, whether these glycoproteins are the targets for nAbs elicited through
infection, as in KSHV infected individuals, and whether these glycoproteins can induce
nAbs in immunized humans, remain to be determined.

Herpesviruses initiate infection via binding to various receptors on the surface of target
cells. This process is primarily mediated by multiple viral glycoproteins embedded in the
viral envelope (Subramanian et al., 2008). These glycoproteins play important roles in virus
attachment to target cells, fusion of the viral envelope with either cytoplasmic or
endosomal membranes, as well as the virion morphogenesis and egress (Gao et al., 1996).
KSHV incorporates eight glycoproteins into its virion envelope: ORF8 (gB), ORF28,
ORF68, ORF22 (gH), ORF47 (gL), ORF39 (gM), ORF53 (gN) and gpK8.1 (Zhu et al.,
2005). Studies have shown that distinct envelope glycoproteins are involved in KSHV
infection of different cell types with gpK8.1, gB, and gH/gL as the major players
(Chakraborty et al., 2012; Chandran, 2010; Mohl et al., 2019). The current model for
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KSHV infection of most cell types suggests that virion binding is mainly initiated via gB
or gpK8.1 interactions with the host cell heparin sulfate (HS) or integrin proteins, which
then trigger gH/gL engagement with the ephrin receptor tyrosine kinases leading to fusion
(Akula et al., 2002; Birkmann et al., 2001; Garrigues et al., 2008; Kerur et al., 2010;
Naranatt et al., 2002; Veettil et al., 2008; Wang et al., 2001). Given the critical roles of
KSHV glycoproteins in viral entry, we hypothesized that KSHV glycoproteins could play
a pivotal role in the elicitation of KSHV-specific nAbs in infected individuals. To test this
hypothesis, we studied the ability of various KSHV glycoproteins in the
adsorption/removal of KSHV-specific nAbs from the plasma of KSHV infected individuals
who have high nAbs titers. Glycoprotein targeted by the nAbs could be identified by a
reduction in the nAbs response after depletion with a specific glycoprotein.

In this unique approach, we have characterized the variable specificity of nAbs
responses in KSHV infected individuals, demonstrating that multiple KSHV glycoproteins
are the targets of KSHV-specific nAbs. There are no differences in their responses in
individuals with either EnKS, EpKS or asymptomatic individuals. The results reveal that
the highest nAbs depletion occurred in the presence of the gH/gL complex, and this activity
was evident in the majority of KSHV infected individuals. Thus, suggesting that gH/gL
complex is the most prominent target of KSHV-specific nAbs, and therefore the most
plausible antigenic target for prophylactic vaccine development against KSHV.
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Study Cohort

The study cohort was comprised of 25 individuals from Zambia and Tanzania: 21 KS
patients and 4 asymptomatic KSHV seropositive participants. Among the KS patients,
there were 15 EpKS and 6 EnKS individuals, while the non-KS participants were consisted
of one HIV-1- and 3 HIV-1+ individuals (Table 1). The age of the study subjects ranged
from 24 to 68 years old, with a median of 27 years for EnKS, 41 years for EpKS and 39
years for non-KS participants. All the EnKS cases were male, while 73.3% of the EpKS
cases were male, and all the non-KS cases were female (Table 1). The duration of
symptomatic KS ranged from 2 months to 108 months, with a median of 12 months for
EnKS and 24 months for EpKS. Majority of the EpKS patients were on anti-retroviral
treatment and had HIV-1 plasma viral load below detection limits. The 1/ IC50 which
indicates the dilution of plasma that accomplish 50% inhibition of KSHV infection was
performed using neutralization assays to determine the KSHV-specific nAbs titers in the
plasma. The KSHV sero-status and total anti-KSHV antibody titers for all participants were
determined by immunofluorescence assay (IFA). Both the total anti-KSHV antibody and
KSHV-specific nAbs titers were variable among KSHV infected individuals. For the
available samples, the presence of KSHV virions in plasma was analyzed by PCR for the
KSHV ORF26 gene. All participants in this cohort are high neutralizers as defined by our
flow cytometry-based neutralization assay (supplementary figure 2).
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KSHV envelope glycoprotein expression in 293T cells

Plasmids encoding KSHV envelope glycoproteins, gB, ORF28, ORF68, gH, gL, gM,
gN and gpK8.1, were generated by cloning the full length sequence of each gene into the
pcDNA3.1 mammalian expression vector (Figure 1A). To facilitate the detection of these
glycoproteins, the sequence for the 3xFLAG epitope tag was fused to the carboxylterminus of each glycoprotein construct, the expression of which was evaluated after
transfection of 293T cells. At 72-hours post-transfection, expression of all KSHV
glycoproteins were detected in the whole cell lysates of their respective transfected cells
using immunoblotting against the 3xFLAG epitope tag (Figure 1B). However, since the
input plasmids transfected into the cells was based on total DNA amount, rather than equal
copy number, there are some variation in expression among different glycoproteins.

Expression of KSHV glycoproteins in transfected 293T lysates does not necessarily
demonstrate whether these proteins were on the cell surface in significant quantities. To
verify their cell surface expression, the cellular membrane fraction was extracted from
293T cells at 72-hours post-transfection with commercially available membrane extraction
reagents. The cell surface expression of the different KSHV glycoproteins was then
confirmed by immunoblotting against the 3xFLAG epitope tag in the extracted plasma
membrane fractions (Figure 1C). The purity of the extracted membrane fraction was
validated by the significantly lower amount of GAPDH protein in comparison to the
cytosolic fraction on immunoblot (Data not shown). For most of the KSHV glycoproteins,
their corresponding bands, as reported by other groups, were detected by immunoblot in
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both the total cell lysates and membrane fractions (Barasa et al., 2017; Chandran, 2010;
Dollery et al., 2019; Zhu et al., 2005). However, the molecular weight of the gM protein in
our study is higher than its theoretical size of 45 kDa. To determine the cause of this
unexpectedly high molecular weight of gM protein, the gM expression plasmid was
sequenced, but no mutation was found. Furthermore, post-translational glycosylation was
also ruled out with Endo H treatment, where the molecular weight of gM remained
unchanged after treatment (Data not shown). Further investigation on how posttranslational modifications such as phosphorylation affected the size of gM protein will be
warranted.

To further confirm the expression and transfection for each glycoprotein and to
demonstrate that the majority of the transfected cells indeed express the glycoproteins, IHC
staining against the 3xFLAG epitope tag was performed on the transfected cell cultures in
situ at 72-hours post-transfection. Since previous studies suggested that gH and gL form a
noncovalent complex that is necessary for efficient transport of gL to the cell surface, cotransfection of gH/gL was also investigated (Hahn et al., 2009). Likewise, due to the
previous reports that gN is required for functional processing of gM and together they form
heterodimers, co-transfection of gN/gM was included as well (Koyano et al., 2003). In
agreement with the immunoblot results, the IHC demonstrated intense brown color stained
cells, indicating high protein expression for all the KSHV glycoproteins in transfected cells
(Figure 2A). Importantly, majority of the cells in the transfected culture expressed their
respective KSHV glycoprotein, demonstrating high transfection efficiency of each KSHV
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glycoprotein encoding plasmid. Non-transfected and empty-vector transfected 293T
controls produced no evident chromagen deposition.

Additionally, to demonstrate KSHV glycoproteins are indeed expressed on the
transfected cell surface and are recognized by KSHV antibodies present in KSHV infected
plasma, IFA was performed on non-permeabilized 293T cells at 72-hours post-transfection
using a pooled plasma from all the study participants (n = 25) as the primary detection
antibody. The cell surface expression of all the KSHV glycoproteins were confirmed by
the presence of green colored cells (Figure 2B). Among the glycoproteins, the signal for
ORF28, ORF68, gL alone and gM alone were relatively weak, which could be due to low
levels of antibodies against these proteins in the pooled plasma. Whereas, the relatively
stronger green color signals in the gH/gL or gM/gN co-transfected cells, in comparison to
their respective single plasmid transfected cells, indicated the interaction between gH/gL
or gM/gN as reported by others which may explain why the complexes are better
recognized by KSHV infected plasma (Hahn et al., 2009; Koyano et al., 2003). No signal
was detected in the non-transfected and empty vector transfected 293T cells.

Antigenic determinant of KSHV-specific nAbs in the plasma of KSHV infected
individuals

To determine which KSHV glycoprotein(s) are the target for KSHV-specific nAbs in
the plasma of non-KS individuals and KS patients, 293T cells expressing various KSHV
glycoproteins were incubated with the patient plasma (n = 25) to adsorb nAbs against
specific glycoproteins. The residual neutralizing capability of the depleted plasma was then

41

quantified in a flow-cytometry based neutralization assay. If nAbs against a specific KSHV
glycoprotein were prevalent in a plasma, depletion by the 293T cells expressing that
particular glycoprotein would result in reduction in the ability of the depleted plasma to
neutralize KSHV infection. These neutralization titers were then normalized with the
percent neutralization of the identical plasma absorbed with empty vector transfected cells
and reflected as a relative percent nAbs absorbed.
Among the 15 EpKS cases, 80% of the patients’ plasma contain nAbs that can
recognize 8 out of 10 variations of the KSHV glycoproteins examined (Figure 3A). Only
patients 21001, 21052 and TIL020 have nAbs that recognize less than 50% of the KSHV
glycoproteins. Despite this breadth of KSHV glycoprotein recognition, the magnitude of
neutralization attributable to each glycoprotein varied widely among individuals. For
instance, ORF28 recognized nAbs responses at higher levels in patient 21017 than patient
3122. Similar patterns of nAbs breadth and magnitude were detected in the 6 EnKS and 4
non-KS cases (Figure 3B and C, respectively). Interestingly, among the entire cohort, only
the gH/gL complex was consistently recognized by the majority of patients nAbs at high
levels. In comparison to other KSHV glycoproteins, the near 80% response to gH/gL was
significantly higher than that against all other glycoproteins or complexes (p-values ranged
p < 0.001 to p <0.0001) (Figure 4). Additionally, there is no correlation between the gH/gLspecific nAbs with the total anti-KSHV and total KSHV-specific nAbs responses, despite
80% of our study participants had demonstrated high level of nAbs against the gH/gL
complex (Supplementary Figure 3A and B). Further no correlation was found between the
nAbs responses against gH/gL complex and age, sex or symptomatic KS duration (among
KS cases) in the cohort (supplementary Fig. 3C to E).
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Similar nAb responses towards KSHV glycoproteins regardless of KS status

Our lab has previously shown that the magnitude of total KSHV nAbs responses are
indistinguishable between EpKS and EnKS, but are significantly higher in KS patients than
non-KS individuals (Lidenge et al., 2019). To determine if these observations extend to the
KSHV glycoprotein-specific nAbs responses, the relative percent nAbs depleted by each
KSHV glycoprotein was compared between the EpKS, EnKS and non-KS groups. Unlike
total KSHV nAbs responses, the KSHV glycoprotein-specific nAbs responses were not
statistically different between KS and non-KS groups (Figure 5). Thus, although the
development of KS increased the magnitude of total nAbs in symptomatic patients, it had
no detectable effect on the breadth and glycoprotein specificity in that increased response.
Additionally, co-infection with HIV-1 seems to have no significant effect on the nAbs
responses.
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Discussion
Neutralizing antibodies are a powerful defense against many viral infections in animals
and humans (Iwasaki, 2016). The nAbs against infections caused by viruses, such as
influenza and flavivirus, have been shown to prevent viral infection, thus it suggests that a
similar approach may also be feasible in preventing KSHV infection (Han and Marasco,
2011; Sui et al., 2009; Whitehead et al., 2007; Wrammert et al., 2008). Although, KSHVspecific nAbs did not prevent the development of KS, whether the presence of these nAbs
prior to exposure to KSHV would prevent infection is still unclear (Kumar et al., 2013).

Since KSHV envelope glycoproteins are incorporated onto the viral surface and are
critical for viral entry into permissive cells, they are the candidate antigens for eliciting
nAbs through vaccination. In recent years, several studies have shown that immunizing
mice or rabbits with Newcastle disease virus-like particles (VLP) expressing KSHV
gpK8.1, gB and gH/gL, either alone or together, can elicit nAbs responses against KSHV
(Barasa et al., 2017; Mulama et al., 2019). However, whether these glycoprotein-targeted
responses are consistent with those in KSHV infected individuals with strong neutralizing
responses have not been investigated. Addressing this question could provide insights for
the design of prophylactic vaccines against KSHV.

Our study is the first to define the specificities of nAbs responses, within plasma of
KSHV infected individuals, against KSHV envelope glycoproteins. In addition, ours is the
first study to investigate whether differentials in magnitude or breadth of nAbs specificities
exist between EnKS, EpKS and non-KS individuals. To ensure that our results were not
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affected by the different KSHV glycoproteins expression, equal copy number of each
glycoprotein encoding plasmid were transfected into equal number of cells, which was then
used for the adsorption of nAbs from sample plasma with optimized number of cells and
temperature (Supplementary figure 1B and 1C). A good example to support our assessment
that the protein expression did not affect the adsorption result, will be gpK8.1, which was
highly expressed in transfected cells based on the immunoblot, IHC and IFA data, but only
small amount of nAbs were adsorbed by it. Using our optimized assays, we found that the
neutralizing component of plasma in a majority of the study participants targeted multiple
KSHV envelope glycoproteins. Although these glycoproteins can elicit nAbs in infected
individuals, the magnitude of the neutralization response varies widely among individuals
with some glycoproteins eliciting much stronger response in one individual than another.
This strongly indicates that nAbs responses elicited by any KSHV envelope glycoprotein
are highly individualized.

Among all the KSHV glycoproteins, only the gH/gL complex elicited nAbs responses
that are consistent and comparable among most individuals. 80% of study participants
showed high levels of nAbs against the gH/gL complex. Given this consistently strong
nAbs reaction against gH/gL from different individuals, we speculate that gH and gL may
undergo conformational changes when complexed, which then expose yet-to-be
determined epitopes that are highly immunogenic, resulting in its high recognition by over
80% of the infected individuals. Interestingly, several individuals such as patients 21062
and TIL002, had nAbs that recognized both gH/gL and gM/gN, while other individuals
also have similar nAbs among different glycoproteins. One possible explanation for this
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observation could be that some nAbs are targeting the carbohydrate moieties, which might
be common among different KSHV envelope glycoproteins. For example, studies have
shown that KSHV gB is associated with high levels of mannose which could be targeted
by KSHV-specific nAbs, but only in some individuals (Baghian et al., 2000). Another
possibility is the presence of nAbs that recognize certain yet-to-be determined
conformational epitopes that may only be exposed when the KSHV glycoproteins interact
with one another. This is feasible if these glycoproteins are in close proximities with one
another on the virion surface. Unfortunately, there is very little information on the KSHV
glycoprotein homo- or hetero-oligomeric structures and certainly none for those on the
KSHV virion, therefore, more studies will be needed to confirm our observation.

Although our previous finding indicated that the total KSHV nAbs responses are
similar in EnKS and EpKS, and that these responses are higher compared to non-KS
individuals, we found no evidence for such differences in terms of nAbs specificities
against different KSHV glycoproteins (Lidenge et al., 2019). Thus, it would appear that
the diversity of KSHV glycoproteins-specific nAbs responses is independent of KS disease
progression, whereas the magnitude of the total KSHV nAbs response increases with
disease progression, and both are independent of HIV-1 co-infection. We also did not find
any correlation between KSHV glycoprotein-specific nAbs responses and the presence of
KSHV virions in the plasma at the time of sampling. This may indicate that there is a tissue
reservoir that is providing the necessary antigens to elicit humoral responses or these are
anamnestic responses from previous episodes of higher plasma viral load.
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In summary, our data suggest that the KSHV glycoproteins gH/gL complex is the most
prominent target for elicitation of nAbs in KSHV infected individuals regardless of KS
status. Thus, the KSHV glycoproteins gH/gL complex should be included as a potential
antigen in future KSHV prophylactic vaccine design.
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Materials and methods

Ethics statement

Written informed consent was obtained from all study participants from Tanzania and
Zambia for sample collection and testing. The study was conducted in accordance with the
Declaration of Helsinki and approved by the review boards of Tanzania National Institute
for Medical Research, Ocean Road Cancer Institute, University of Zambia Biomedical
Research Ethics Committee and the University of Nebraska-Lincoln (Tanzania CRITIC:
IRB Number: 20141014709FB, and Zambia ZAMDAPP: IRB Number: 20170817442FB).

Cell cultures
Human embryonic kidney T (293T) and BC-3 cells were obtained from ATCC (CRL3217 and CRL-2277, respectively). 293T cells were maintained in Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (P/S). BC-3 cells were maintained in RPMI with 20% FBS and 1% P/S.
Vero.219 cells [a gift from Jeffrey Vieira (Vieira and O'Hearn, 2004)] stably expressing
green fluorescent protein from the KSHV genome during latency were used to generate
recombinant KSHV (rKSHV.219) and were maintained in DMEM with 10% FBS and 1%
P/S and 6 µg/ml of puromycin. All cell cultures were maintained at 37°C in a 5% CO 2
incubator.
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KSHV serological assays
The KSHV sero-status and total anti-KSHV antibody titers were determined by
immunofluorescence assay (IFA) on activated BC-3 cells as previously described (Minhas
et al., 2008). To determine the total KSHV-specific nAbs titer, neutralization assays were
carried out in triplicate as previously described (Kumar et al., 2013). Briefly, heatinactivated plasma (56°C for 1 hour) from study participant was incubated with
rKSHV.219 virus at 1:50 dilution at 37°C for 1 hour. 293T cells seeded in 96-well plates
(2.5 X 104 cells/well) were infected with the virus-plasma mixture, centrifuged (400 X g
for 20 minutes) and then incubated for 72-hours at 37°C. Neutralization activity of the
plasma, relative to a KSHV negative plasma, was then quantified by flow cytometry at 72hours post-infection as followed:
S
% 𝑛𝑒𝑢𝑡𝑟𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 = 100 − [( ) 𝑋 100]
C
S = % GFP positive cells in wells with KSHV positive plasma.
C = % GFP positive cells in wells with KSHV negative plasma control.

Plasma samples that were positive for KSHV nAbs at the 1:50 dilution were further
titrated by 2-fold dilutions from 1:50 to 1:3200 to define the IC50 (50% inhibitory
concentration).

HIV-1 serology and plasma viral load quantification by real-time PCR

The HIV-1 diagnosis was made according to Alere Determine HIV-1/2 Ag/Ab Combo
test in Zambia and Tanzania HIV Rapid Test Algorithm. The HIV-1 serology results were
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verified using HIV-1–2.0 First Response kit (Premier Medical Corporation Ltd). To
quantify HIV-1 plasma viral load, the viral RNA was extracted from plasma following the
QIAamp viral RNA extraction protocol (Qiagen) and measured using the RNA Ultra-Sense
One-Step quantitative real-time PCR (qPCR) system (Applied Biosystems) as previously
published (Tso et al., 2018).

KSHV virion in plasma

Plasma of study participants (400 µl) were centrifuged at 8000 X g at room temperature
for 10 minutes to remove residual cells. Then 15 µl of DNase-I (Qiagen) was added to each
sample and incubated for 2-hours at room temperature to digest cell-free genomic DNA.
The samples were then incubated at 65°C for 20 minutes to inactivate DNase-I, and viral
DNA was extracted by the QIAamp DNA mini kit according to the manufacturer’s protocol
(Qiagen). The presence of KSHV virion in plasma was then determined by nested-PCR of
the extracted viral DNA using primers for the open reading frame 26 (ORF26) amplicon
(forward

[5’-AGCCGAAAGATTCCACCAT-3’]

TCCGTGTTGTCTACGTCCAG-3’]

in

CGAATCCAACGGATTTGACCTC-3’]

the

first
and

and
round,

reverse
and
reverse

forward

[5’[5’[5’-

CCCATAAATGACACATTGGTGGTA-3’] in the second round reaction) under
conditions previously described (Lidenge et al., 2019). Contamination of the extracted viral
DNA by cell-free genomic DNA was ruled out through a negative PCR result for the human
β-actin gene.
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KSHV envelope glycoprotein constructs
To construct the KSHV gB, gpK8.1, gH/gL, gM, gN, ORF28 and ORF68 3XFLAG
tagged plasmids, the full length sequence of individual glycoproteins was PCR-amplified
from BC-3 genomic DNA and cloned into the pcDNA3.1 mammalian expression vector
(Invitrogen) with a 3xFLAG fused to the carboxyl-terminus of each glycoprotein. The
resulted plasmids were confirmed with restriction enzyme digestions and sequencing.
Immunoblot
1 x 106/well of 293T cells were seeded into 6-well plates. At 24-hours post-seeding, 2
µg of each KSHV glycoprotein expressing plasmids were transfected into the 293T cells
using FuGENE 6 transfection reagent (Promega). After 72-hours, the cellular membrane
fraction of the transfected cells was extracted by lysing the cells, in the presence of
proteinase inhibitor cocktail (Thermo Scientific), with Mem-PER eukaryotic membrane
protein extraction reagent according to the manufacturer’s protocol (Thermo Scientific).
The total cell lysis of the transfected cells was obtained by the lysing the cells in RIPA
lysis buffer with proteinase inhibitor cocktail (Thermo Scientific). The extracted protein
was then measured by Pierce BCA protein assay (Thermo Scientific) and equal amount of
protein for each glycoprotein was loaded and resolved in a 4-15% gradient SDS-PAGE
(Bio-Rad). The proteins were then transferred onto a nitrocellulose membrane and blocked
with 5% skim milk in 1X PBS with 0.5% Tween 20 for 2-hours at room temperature. The
membranes were then incubated with either mouse monoclonal anti-FLAG M2 antibody
(Sigma-Aldrich) at 1:100 or mouse monoclonal anti-GAPDH (6C5) IgG (Santa Cruz
Biotechnology) at 1:2000 overnight at 4°C. Next day, after washing, the membranes were
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incubated with donkey anti-mouse 800CW or 680CW antibodies (Li-Cor Biosciences) at
1:10000 for 2-hours at room temperature, and then washed repeatedly. The membranes
were then visualized with Odyssey infrared imager (Li-Cor Biosciences).
Immunohistochemistry (IHC)
1x 104/chamber of 293T cells were seeded into 4-well chamber slides. At 24-hours
post-seeding, equal copy number of KSHV glycoprotein expressing plasmids were
transfected into 293T cells using FuGENE 6 transfection reagent (Promega). After 72hours, the slides were washed and fixed in 4% paraformaldehyde for 30 min at room
temperature. The fixed slides were then incubated in 0.3% H2O2 methanol solution for 30
minutes at room temperature, followed by washes and antigen retrieved in sodium citrate
solution for 15 minutes at 98°C. After cooling to room temperature, the slides were washed
and blocked with 10% normal goat serum for 30 minutes at room temperature and
incubated with mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich) at 1:300 in
blocking solution at 4°C overnight. The next day, the slides were washed and incubated
with Dako EnVision+ System-HRP anti-mouse polymer for 30 minutes at room
temperature and color was developed with DAB solution (Dako). Counterstaining of the
nucleus was performed using hematoxylin. The final stained slides were then air-dried,
rinsed twice in xylene solution for 5 minutes each and coverslip was added with Cytoseal
60 (Thermo Scientific). The slides were examined with a Nikon Eclipse 50i microscope
under 20X magnification. Three times 3 fields of pictures (i.e., 9 pictures) were taken at
20X magnification and digitally stitched using NIS-Elements imaging software (Nikon).
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Immunofluorescence assay for protein expression
5 x 104/chamber of 293T cells were seeded into 8-well chamber slides. At 24-hours
post-seeding, equal copy numbers of KSHV glycoprotein expressing plasmids were
transfected into 293T cells using FuGENE 6 transfection reagent (Promega). After 72hours the slides were washed and fixed in 4% paraformaldehyde for 30 minutes at room
temperature. The fixed slides were incubated with a heat inactivated (56°C for 1 hour)
pooled plasma from all the study subjects at 1:40 at 4°C overnight. Next day, the slides
were washed and incubated with mouse monoclonal anti-human antibody (ATCC, CRL1786) at 1:4 at 37°C for 1 hour. Then the slides were washed and incubated with CY2
AffiniPure donkey anti-mouse IgG (H+L) antibody (Jackson ImmunoResearch) at 1:200
at 37°C for 1 hour. Next, the slides were washed and stained with 0.001% Evans blue for
5 minutes at room temperature. After staining, the slides were washed and coverslip with
mounting media. The slides were examined with a Nikon Eclipse 50i microscope under
20X magnification.
rKSHV.219 Production
A total of 18 x 106 Vero.219 cells per flask were seeded into T-225 flasks. At 24-hours
post-seeding, the culture medium was removed and 3300 viral particles of adenovirus type
5 encoding KSHV RTA (Ad5-RTA) (gift from Dr. Jean Gustin) were incubated with the
cells in the presence of 5M valproic acid without (w/o) puromycin. Next day, the cells were
washed and fresh medium w/o valproic acid and puromycin was added. After 48-hour the
supernatant was collected and was cleared by a 10 minutes spin at 2000 rpm. Then, the
supernatant was collected and concentrated through a 20% sucrose cushion by 2-hours spin
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at 28000 rpm. The virus pellet was re-suspended in medium and tittered on 293T using
flow cytometry for measuring GFP positive cells to determine the amounts of virus needed
to achieve 40-50% GFP positive cells in the neutralization assays (supplementary figure
1A).
KSHV glycoproteins transfected 293T cells absorption of nAbs from plasma
Thirteen µl of the heat inactivated plasma (56°C for 1 hour) was incubated with 1 x 106
293T cells (transfected with equal copy number of KSHV envelope glycoprotein plasmids
either individually or in combination) in 578 µl volumes of medium (DMEM containing
10% FBS, 1% P/S and 1% protease inhibitor cocktail) at 4°C overnight. The number of
cells and temperature used for absorption were optimized based on the gH/gL complex
(Supplementary figures 1B and C). After incubation with the KSHV glycoproteins
expressing 293T cells, the plasma-cell mixture was spun down at 6000 X g for 5 minutes
to remove the cell pellets, and the supernatant was collected. Then neutralization assays
were performed in triplicate, the supernatant was incubated with 59 µl of rKSHV.219 at
37°C for 1 hour. 293T cells in 96-well plates (2.5 x 104 cells/well) were then infected with
virus-plasma mixture, centrifuged (400 X g for 20 minutes at room temperature) and
incubated for 72-hours. Neutralization was quantified by flow cytometry at 72-hours postinfection. The percentage of neutralization was defined as followed:
S
% 𝑛𝑒𝑢𝑡𝑟𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 = 100 − [( ) 𝑋 100]
C
S = % GFP positive cells in wells with KSHV glycoproteins absorbed sample plasma.

54

C = % GFP positive cells in wells with pooled plasma from HIV-1 and KSHV doublenegative donors (n = 10).
The percentage of nAbs absorption was defined as followed:
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 % 𝑛𝐴𝑏𝑠 𝑎𝑑𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 = [

B−N
] 𝑋 100
B

N = % neutralization of KSHV glycoproteins absorbed sample plasma.
B = % neutralization of sample plasma absorbed with empty vector transfected 293T cells.

Statistical Analysis
Statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software
Inc). The comparison of nAbs responses to gH/gL complex with other KSHV glycoproteins
among all the participants was performed using the Mann Whitney test. The comparison
of nAbs responses to each KSHV glycoprotein in the EnKS, EpKS and non-KS groups was
performed using the Mann Whitney test. Correlation between the extent of nAbs absorbed
by gH/gL and total anti-KSHV and nAbs responses was performed using the nonparametric
Spearman correlation analysis.
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Figure Legends

Figure 1. KSHV envelope glycoprotein constructs and their expression in 293T cells
by immunoblot. (A) Schematic representation of pcDNA3.1 mammalian expression
vector encoding KSHV glycoproteins fused with 3xFLAG at the C-terminus of each
glycoprotein (not drawn to scale). (B) KSHV glycoproteins expression was demonstrated
in the whole cell lyses of transfected 293T cells by immunoblot against the 3xFLAG tag.
(C) KSHV glycoproteins expression on the cell surface was demonstrated in the extracted
membrane fractions by immunoblot against the 3xFLAG tag.

Figure 2. KSHV envelope glycoproteins expression in 293T cells by IHC and IFA.
KSHV glycoproteins expression was confirmed in 293T cells at 72-hours post-transfection
by IHC against the 3xFLAG tag. (B) The cell surface expression of KSHV glycoproteins was
confirmed by IFA on non-permeabilized 293T cells at 72-hours post-transfection with pooled
plasma from all study participants. Pictures were taken at 20X magnification.

Figure 3. Antigenic determinant of KSHV-specific nAbs in the plasma of KSHV infected
individuals. Heat inactivated plasma of the study participants were absorbed with KSHV
glycoproteins expressing 293T cells and neutralization assays were carried out as described in
material and methods. The relative percent of nAbs absorbed was shown for (A) EpKS cases, (B)
EnKS cases and (C) Non-KS (asymptomatic KSHV infected) cases.

Figure 4. Comparison of nAbs responses among various KSHV envelope glycoproteins. The
gH/gL complex-specific nAbs response was compared with other KSHV glycoproteins among all
the participants using the Mann Whitney test (*** p<0.001, **** p<0.0001).
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Figure 5. Comparison of nAbs responses to each KSHV glycoprotein in the EnKS, EpKS and
non-KS groups. The nAbs responses against each KSHV glycoproteins was compared between
the EnKS, EpKS and non-KS individuals using the Mann Whitney test.

Supplementary Figure 1. Titration of rKSHV.219, optimization conditions for
adsorption of plasma with KHSV glycoprotein expressing 293T cells. (A) rKSHV.219
titration in 293T cells. 293T cells were seeded at a density of 2.5 x 106 in triplicates into a
96-well plate. The cells were then infected with 10, 20, 30, 40, 60 or 80 µl of concentrated
virus in a total volume of 200 µl for 72 hours at 37°C. Infected cells (GFP+ cells) were
quantified using FACS by acquiring a total of 10,000 events. (B) Optimization of binding
temperature during absorption of nAbs with gH/gL complex expressing 293T cells. (C)
Optimization of the number of gH/gL complex expressing 293T cells during absorption
with nAbs.

Supplementary Figure 2. Total KSHV-specific nAbs of the study participants.
Neutralization assays were conducted by incubating rKSHV.219 with plasma at 1:50
dilutions. The level of neutralization was determined after 72 hours using flow cytometry
to quantify the number of GFP+ cells acquiring a total of 10000 events.

Supplementary Figure 3. Comparison of the magnitude of nAbs responses to KSHV
gH/gL complex with; total anti-KSHV antibodies and with total KSHV-specific nAbs
responses, age, sex and symptomatic KS duration. The correlation between the extent
of nAbs absorbed by gH/gL and (A) total anti-KSHV and (B) nAbs responses, (C) age, (D)
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sex and (E) symptomatic KS duration was performed using nonparametric Spearman
correlation analysis (ns P>0.05).
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Figures
Table 1. Characteristics of the study
cohort
Patien
Sex
t ID
3096 M
3111 M
Endemic
KS
3135 M
(KSHV+,HIV3137 M
1-)
3139 M
21182 M
3060 F
3080 F
3122 M
21001 F
21009 M
21017 M
21021 M
21028 M
Epidemic
KS 21052 F
(KSHV+,HIV- 21053 M
1+)
21062 M
TIL00
M
2
TIL00
7
M
TIL01
8
M
TIL02
0
M
Non-KS
(KSHV+, HIV- 3067 F
1-)
21598 F
Non-KS
(KSHV+, HIV- 594 F
1+)
649 F

Age

KS
months

HIV-1
months

27
24
25
51
27
57
44
21
34
36
36
38
41
30
37
44
68

3
7
12
NI
14
108
8
3
3
18
60
24
60
24
84
9
24

NA
NA
NA
NA
NA
NA
12
5
24
168
120
36
NI
24
NI
5
NI

HIV-1 plasma
ARV
viral
load
months
[copies/ml]
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
BDL
9
BDL
1
BDL
24
BDL
10
BDL
9
BDL
36
1.16E+05
NI
BDL
24
BDL
48
BDL
4
BDL
NI

68

3

48

2201

36

285.2

46

72

72

33

72

407.1

55

48

120

BDL

120

1600.5

51

2

7

BDL

7

454.4

10240 NI

60

NA

NA

NA

NA

224.6

5120

NI

45
33
25

NA
NA
NA

36
18
6

NI
NI
NI

NI
12
4

197.1
175.4
126.1

2560
2560
640

NI
NI
NI

1/ IC50

IFA

Plasma ORF26
PCR

395.1
438.9
1672.4
292.2
281.8
115.7
1259.4
199.9
2779.9
605.3
232.2
845.7
1606.7
1167.5
1971.7
890.4
715.8

20480
5120
5120
5120
40960
10240
40960
1280
40960
2560
1280
1280
1280
5120
2560
2560
5120

+
NI
+
+
+
+
+
+

5120
5120
5120

‘+’ denotes KSHV virions present in plasma, and ‘-’ denotes KSHV virions not present in
plasma.
Abbreviations: KSHV, Kaposi;s sarcoma-associated herpesvirus; KS, Kaposi sarcoma; HIV-1, human immunodeficiency virus type 1; ARV,
Antiretrovirals; IFA, Immunofluorescence assay; NA, not applicable; NI, no information; BDL, below detection limit.
IFA numbers represent total anti-KSHV antibody titer (reciprocal endpoint plasma dilution); 1/ IC50 numbers represent the dilution of plasma that has a
50% neutralizing activity.
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NI
NI
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Discussion and concluding remarks
Neutralizing antibodies can be very effective in controlling some viral infections in
humans (Iwasaki, 2016). Studies have shown that the nAbs against KSHV are not
protective against KS since most KS patients have high titers of these antibodies, however,
it is still not clear whether having KSHV-specific nAbs prior to exposure to KSHV could
be beneficial in preventing its infection, and therefore could serve as an adaptive correlate
of protection against KS development. (Kumar et al., 2013). In addition, the targets of the
human KSHV-specific nAbs and whether these antibodies can be induced by a KSHV
vaccine needs to be determined. Addressing these questions could provide insights for the
design of an effective prophylactic vaccines against KSHV and KS development.
Studies on KSHV gB have demonstrated that this glycoprotein plays a major role in
KSHV binding and entry into targets cells, hence, making it an attractive antigenic target
to elicit nAbs against KSHV (Akula et al., 2001a, 2002; Akula et al., 2001b; Veettil et al.,
2008; Wang et al., 2003). Immunization of mice with Ad-gB induced humoral immune
responses, resulting in moderate, about 45-65%, neutralizing activity by the immunized
plasma at 1:18 dilution. Because only moderate levels of neutralization were observed with
Ad-gB immunized mice plasma, other KSHV envelope glycoproteins can be involved in
eliciting stronger nAbs responses.
Characterization of the human KSHV-specific nAb responses against all the KSHV
envelope glycoproteins revealed adsorption of KSHV-specific nAbs by different KSHV
envelope glycoproteins, suggesting that multiple KSHV envelope glycoproteins are the
targets for KSHV-specific nAbs in KSHV infected individuals. However, the extent of
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adsorption by each KSHV envelope glycoprotein varied among the KSHV infected
individuals, indicating that the neutralizing responses against any KSHV envelope
glycoprotein varies in magnitude among KSHV infected individuals. Among all the KSHV
glycoproteins, only the gH/gL complex elicited nAbs responses that are consistent and
comparable among most individuals. About 80% of the participants showed high levels of
nAbs adsorption against gH/gL glycoprotein. This implies that gH/gL is the most
prominent target of KSHV-specific nAbs in humans. Consequently, having nAbs against
gH/gL glycoprotein could possibly prevent the infection by KSHV. Hence, gH/gL
glycoprotein is a potential antigen target for developing prophylactic vaccines against
KSHV.
In an effort to compare KSHV immune responses between endemic KS and epidemic
KS patients, it was recently shown that the total KSHV nAb responses are similar in
endemic KS and epidemic KS, but higher than those in non-KS individuals (Lidenge et
al., 2019). By comparing neutralizing antibody responses against KSHV envelope
glycoproteins in endemic KS, epidemic KS and non-KS individuals, it was concluded that
there is no significant difference in neutralizing responses against any KSHV envelope
glycoprotein between these groups. These results suggest that the neutralizing responses
against KSHV envelope glycoproteins varies among KSHV infected individuals, and there
is no correlation with HIV-1 co-infection and KS disease progression.
Previous studies have focused exclusively on immunizing mice and rabbits with
various recombinant KSHV glycoproteins to identify those that induced nAbs in the
animals, but failed to reflect whether they would induce similar nAbs in humans. To
understand what KSHV antigens trigger the induction of human nAb responses, this study
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was conducted to characterize the KSHV-specific nAb responses in KSHV individuals to
identify the potential targets of their responses upon natural KSHV infection. In summary,
our results demonstrate that KSHV-specific nAb responses in humans vary among KSHV
infected individuals, and multiple KHSV envelope glycoproteins can be the targets of these
nAbs, with gH/gL glycoprotein being the most predominant target.
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